#Poland - #Influenza A #H5N1 viruses of high pathogenicity (Inf. with) (non-poultry including wild birds) (2017-) - Immediate notification

 

A wild Greylag Goose in Lubelskie Region.

Source: 

Link: https://wahis.woah.org/#/in-review/7227

____

#Hungary - High pathogenicity avian #influenza #H5N1 viruses (Inf. with) (#poultry) - Immediate notification

 

Poultry farms in Békés Region.

Source: 

Link: https://wahis.woah.org/#/in-review/7228

____

#Genomic #features associated with sustained #mammalian #transmission of avian #influenza A viruses

 

Abstract

Comparably few lineages of influenza A virus (IAV) have evolved long-term sustained transmission in mammals. The reasons remain largely unknown, and the possibility of avian IAVs evolving sustained mammalian transmission is an ongoing concern. Here we measured the GC content and frequency of GC dinucleotides in 115,520 whole genomes of IAVs using bioinformatic analyses. We found that persistent mammalian lineages showed declining trends in GC-related content and could be reliably separated from IAVs circulating only in birds and those sporadically infecting mammals. Similarly, the earliest viruses of persistent mammalian lineages showed reduced GC-related content, suggesting that this trait might in part contribute to their eventual persistence. Recent highly pathogenic 2.3.4.4b H5 viruses that spread in mink, foxes and humans were also characterized by reduced GC-related content. While not sufficient, reduced GC-related content may be a necessary condition for sustained mammalian transmission and should be included in risk assessment tools for pandemic influenza.

Source: 

Link: https://www.nature.com/articles/s41564-025-02257-4

____

Genomic-based #biosurveillance for avian #influenza: whole genome sequencing from wild #mallards sampled during autumn migration in 2022–23 reveals a high co-infection rate on migration stopover site in #Georgia

 

Abstract

The Caucasus region, including Georgia, is an important intersection for migratory waterbirds, offering potential for avian influenza virus (AIV) transmission between populations from different geographic areas. In 2022 and 2023, wild ducks were sampled during autumn migration events in Georgia to study the genetic relationships and molecular characteristics of influenza strains. Sequencing and phylogenetic analysis were used to compare the sampled strains to reference sequences from Africa, Asia, and Europe, allowing assessment of genetic relationships and virus transmission between migratory birds. Protein language modeling identified potential co-infections. Of 225 duck samples, 128 tested positive for the influenza M gene. 55 influenza-positive samples underwent whole-genome sequencing, revealing significant diversity. Analysis of the hemagglutinin (HA) segment showed notable differences among subtypes. Most samples were H6N1 and H6N6, but co-infections with combinations like H6H3, N8N1, N6H9, N2N6, and H9H6/N1N2 were also identified. These findings demonstrate the high variability of influenza viruses in migratory waterbirds in Georgia, including a notable rate of co-infections. Some samples exhibited uncommon genetic characteristics compared to other strains from the same year, suggesting Georgia’s role as a mixing vessel for influenza viruses. This facilitates reassortment during co-infections and contributes to the genetic diversity observed across flyways.

Source: 

Link: https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2026.1735728/full

____

Detection of #LaCrosse Virus #RNA in Clinical #Specimens Obtained from #Children with La Crosse Infection

 

Highlights

• Viremia in children with La Crosse Virus infection is transient; viral RNA was detected in only 3.2% of sera

• Detection of La Crosse Virus RNA in respiratory samples is slightly higher at 21.7% and may reflect the temporal distribution of the virus after infection

• NAAT has limited utility in routine diagnosis of La Crosse Virus encephalitis in children but may still be useful in cases with delayed seroconversion

Abstract

Background

La Crosse virus (LACV), a member of family Peribunyaviridae, genus Orthobunyavirus, is the leading cause of neuroinvasive arboviral infection in children in the United States. Diagnosis relies on detecting specific antibodies (IgG or IgM), a 4-fold titer rise or seroconversion, in patients with compatible presentations. NAAT used for LACV detection has largely been limited to mosquito, animal models or postmortem brain tissue. There is a lack of data on the performance of NAATs in clinical specimens from living patients.

Methods

Children who had positive arbovirus serology tests and a diagnosis of LACV encephalitis were identified. Remnant specimens including plasma, serum, CSF, throat swab (THT) or nasopharyngeal sample (NP) submitted to the laboratory for other diagnostic testing were retrieved and tested with LACV-PCR. Medical records were reviewed for demographics, presenting symptoms and test results.

Results

From June 2015 to October 2021, 61 patients had remnant specimens available for LACV-PCR and were included in this study. A total of 179 clinical specimens from these patients were tested, including 64 sera, 31 plasma, 33 CSF, 23 THT and 28 NP. Ten (5.3%) samples collected from 8 (13.1%) unique patients were positive for LACV RNA. The positive rates were 3.2%, 0, 6.5%, 3.5% and 21.7% for sera, plasma, CSF, NP and THT respectively.

Conclusion

There is limited utility of NAATs for diagnosis of LACV infection. NAATs may be useful in cases with delayed seroconversion or in immunocompromised individuals.

Source: 

Link: https://www.sciencedirect.com/science/article/abs/pii/S1386653226000120?dgcid=rss_sd_all

____

#Oseltamivir and #baloxavir monotherapy and combination #therapy efficacy against clade 2.3.4.4b #H5N1 #influenza virus infection in #ferrets

 

Abstract

Neuraminidase inhibitors (NAIs) and cap-dependent endonuclease inhibitors (CENIs) represent two classes of antiviral drugs recommended for early treatment of patients with seasonal influenza A virus (IAV) infections. However, only limited human data, particularly on combination antiviral treatment, are available to inform optimal dosing regimens against novel IAVs, including highly pathogenic avian influenza A(H5N1) virus, associated with severe disease. Clade 2.3.4.4b A(H5N1) viruses have caused outbreaks in avian and mammalian species worldwide, highlighting the need to assess antiviral drug efficacy against these strains. We challenged ferrets with a D1.1 genotype A(H5N1) virus and treated infected animals with the NAI oseltamivir phosphate (OST) and the CENI baloxavir acid (BXA), alone or in combination, with treatment onset commencing pre- or post-symptom onset (24- or 48-hours post-inoculation (p.i.), respectively). When administered pre- or post-illness onset, BXA, but not OST, monotherapy provided significant reduction of clinical signs and significantly decreased infectious viral levels (in both respiratory and extrapulmonary specimens) compared with mock-treated animals. Combination OST/BXA treatment, when administered pre- or post-symptom onset, resulted in significant improvements in both metrics versus OST monotherapy. These data support continued investigation of antiviral treatment modalities that include both NAI and CENI for patients with mild and severe A(H5N1) disease.

Source: 

Link: https://www.nature.com/articles/s42003-026-09607-w

____

#Marburg virus disease - #Ethiopia [End of the Outbreak] (#WHO, Jan. 26 '26)

 

{Excerpt}

26 January 2026

Situation at a glance

On 26 January 2026, the Ministry of Health of Ethiopia declared the end of the Marburg virus disease (MVD) outbreak. 

This declaration came after two consecutive incubation periods (a total of 42 days) since the last person confirmed with MVD died and was given a safe and dignified burial, in accordance with WHO recommendations on 14 December 2025. 

As of 25 January 2026, a cumulative total of 19 cases, including 14 confirmed (including nine deaths) and five probable cases (all deaths), were reported. 

A total of 857 contacts listed for monitoring all had completed their 21-day follow-up as of 25 January 2026. 

WHO, through its country office and partners, provided technical, operational and financial support to the government to contain this outbreak.

Description of the situation

On 14 November 2025, after the laboratory confirmation of suspected viral hemorrhagic fever (VHF) cases in Jinka town, South Ethiopia Regional State, Ethiopia, the Ministry of Health of Ethiopia declared an outbreak of Marburg Virus Disease (MVD). 

Molecular testing conducted by the National Reference Laboratory at the Ethiopian Public Health Institute (EPHI) identified Marburg virus (MARV) in patient samples. 

This was the first time Ethiopia was reporting a MVD outbreak.

The first known case was an adult from Jinka town who developed symptoms on 23 October. 

The patient presented to the General Hospital the following day with vomiting, loss of appetite, and abdominal cramps. 

As of 25 January 2026, a cumulative total of 14 confirmed cases, including nine deaths (Case Fatality Rate (CFR) 64.3%) and five probable cases, all of whom had died, were reported by the Ministry of Health from Jinka, Malle and Dasench woredas in South Ethiopia Region and Hawassa in Sidama Region.

As of 25 January 2026, a total of 857 contacts were listed who completed 21 days of follow-up, 760 from the South Ethiopia Region and 97 from the Sidama Region. 

As of 5 January 2026, 3800 samples were tested for the virus.

On 26 January 2026, after two consecutive incubation periods (a total of 42 days), without a new confirmed case reported, after the last confirmed case died and was given a safe and dignified burial, on 14 December 2025, the Ministry of Health of Ethiopia declared the end of the MVD outbreak, as per WHO recommendations.

(...)

Source: 

Link: https://www.who.int/emergencies/disease-outbreak-news/item/2026-DON592

____

#Poland - #Influenza A #H5N1 viruses of high pathogenicity (Inf. with) (non-poultry including wild birds) (2017-) - Immediate notification

 

A wild Greylag Goose in Świętokrzyskie Region.

Source: 

Link: https://wahis.woah.org/#/in-review/7224

____

#HK, DH follows up on #Nipah virus #infection cluster in #India (Jan. 26 '26)

 

DH follows up on Nipah virus infection cluster in India

In light of reports indicating a cluster of a Nipah virus infection in a certain region of India, the Centre for Health Protection (CHP) of the Department of Health (DH) said today (January 26) that it has proactively sought further information from the World Health Organization (WHO) and Indian health authorities. 

The CHP is also conducting health screenings on inbound travellers from the affected area who exhibit suspected symptoms, with an aim of promptly referring suspected cases to hospitals for investigation. 

Currently, there are no imported or local cases of Nipah virus infection in Hong Kong.

Preliminary information indicated that a hospital in Kolkata, West Bengal, India, has recorded five confirmed cases of Nipah virus infection since mid-January of this year. 

The cluster was mainly due to nosocomial transmission and primarily involved healthcare workers, with no reported deaths or cross-border transmissions to date. 

Approximately 100 close contacts have been quarantined and tested in India. 

The CHP's current risk assessment indicates a low risk of importation of Nipah virus into Hong Kong.

Nipah virus was first identified during outbreaks in Malaysia and Singapore from 1998 to 1999, affecting pig farm workers and individuals with close contact with pigs. 

It can affect various animals, including pigs, horses, goats, sheep, cats and dogs. 

Over the past two decades, multiple outbreaks of human Nipah virus infections were recorded in Bangladesh and India, typically occurring between December and April. 

Transmission primarily occurs through the consumption of raw date palm sap contaminated by fruit bats. India's most recent outbreak occurred in Kerala in mid-2025, involving four cases.

"Nipah virus infection is an emerging zoonotic disease. Fruit bats are the natural host for the virus. The virus is mainly transmitted through direct contact with sick animals via their contaminated respiratory droplets, nasal secretions and tissues. It can also be transmitted via consuming food contaminated with urine, droppings or saliva from infected bats, usually fruits or fruit products (particularly raw date palm sap). Human-to-human transmission is also possible through close contact with contaminated secretions and excretions of infected persons. Such transmission has been reported in patients' household and healthcare settings," the Controller of the CHP, Dr Edwin Tsui, said.

Patients infected with Nipah virus can be asymptomatic. 

Early symptoms include flu-like symptoms, such as fever, headache, vomiting, sore throat and muscle aches. Other symptoms include dizziness, drowsiness and a decrease in consciousness. Severe cases may develop complications such as pneumonia, seizure, encephalitis, coma or even death. The case fatality rate ranges from approximately 40 per cent to 75 per cent. Among the patients who survive acute encephalitis, around 20 per cent of them may have persistent nerve problems. Currently, there is no specific treatment or medication for Nipah virus infection. The mainstay of treatment is limited to supportive care. Symptoms usually start to develop around four to 14 days after exposure, but onset may occur as late as 45 days.

"Hong Kong has the ability to detect infections of unknown causes and emerging infectious diseases at boundary control points and in hospitals. On the immigration level, the DH conducts medical assessments for sick travellers at all boundary control points and refers them to hospitals for medical examinations as needed. The CHP has a robust communicable disease surveillance and notification mechanism that enables medical professionals to report suspected cases. So far, no cases of Nipah virus infection have been recorded. Although there are no direct flights between Kolkata and Hong Kong, the CHP will step up health screenings for passengers arriving from India at the airport as a precautionary measure. Port Health staff have been arranged to carry out temperature screenings for travellers at relevant flight gates, perform medical assessments on symptomatic travellers and refer suspected cases with potential public health implications to hospitals for examination," said Dr Tsui.

Dr Tsui reminded the public to take the following measures to reduce infection risk if travel to Nipah virus-affected areas is unavoidable:

-- Avoid contact with wild animals or sick farm animals, especially bats, farmed pigs, horses, domestic and feral cats.

-- Avoid areas where bats are known to roost.

-- Observe good personal hygiene; wash hands frequently with liquid soap and water, especially after contact with animals or their droppings/secretions, and after taking caring of or visiting sick people.

-- Observe food hygiene by thoroughly washing and peeling fruits before consumption. Fruits with signs of bat bites or found on the ground should not be consumed. Avoid drinking raw date palm sap, toddy or other juice.

 The CHP will monitor the situation and implement appropriate prevention and control measures based on risk assessments to safeguard public health and the well-being of citizens.

 

Ends/Monday, January 26, 2026

Issued at HKT 19:45

Source: 

Link: https://www.info.gov.hk/gia/general/202601/26/P2026012600674.htm?fontSize=1

____

#Ukraine - #Influenza A #H5N1 viruses of high pathogenicity (Inf. with) (non-poultry including wild birds) (2017-) - Immediate notification

 

Backyard birds in Chernihiv Region.

Source: 

Link: https://wahis.woah.org/#/in-review/7223

____

Pitlessie Fair, David Wilkie (1804)

 

Public Domain.

Source: 

Link: https://www.wikiart.org/en/david-wilkie/pitlessie-fair-1804

_____

#Coronavirus Disease Research #References (by AMEDEO, Jan. 24 '26)

 

Antiviral Res

1. HEDSKOG C, Rodriguez L, Hu Y, Li J, et al
   SARS-CoV-2 Resistance Analyses From the Phase 3 BIRCH Study of Obeldesivir in High-Risk Nonhospitalized Participants With COVID-19.
   Antiviral Res. 2026 Jan 19:106351. doi: 10.1016/j.antiviral.2026.106351.
   PubMed         Abstract available
   
   

   
   BMJ

2. HIGGS J
   Help me piece my story together.
   BMJ. 2026;392:r2624.
   PubMed        
   
   
3. RUSSELL MD, Schaffer A, Bechman K, Gibson M, et al
   Time trends in newly recorded diagnoses of 19 long term conditions before, during, and after the covid-19 pandemic: population based cohort study in England using OpenSAFELY.
   BMJ. 2026;392:e086393.
   PubMed         Abstract available
   
   

   
   Clin Infect Dis

4. WINOKUR P, Diya O, Fitz-Patrick D, Dever M, et al
   Safety and Immunogenicity of a Fourth Dose of Omicron-BA.1-Adapted BNT162b2 COVID-19 Vaccines in Adults 18?55 Years Old.
   Clin Infect Dis. 2026 Jan 21:ciag026. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   Emerg Infect Dis

5. FORD ND, Simeone RM, Pratt C, Saydah S, et al
   Functional Limitations and Illness-Related Absenteeism among School-Aged Children with and without Long COVID, United States, 2022-2023.
   Emerg Infect Dis. 2025;31:11-19.
   PubMed         Abstract available
   
   
6. PRATT CQ, Dalton AF, Koumans EH, Agedew A, et al
   Thrombotic Events and Stroke in the Year After COVID-19 or Other Acute Respiratory Infection.
   Emerg Infect Dis. 2025;31:3-10.
   PubMed         Abstract available
   
   
7. LEIS AM, Womack KN, Maxcy C, Caldwell E, et al
   Long-Term Illness in Adults Hospitalized for Respiratory Syncytial Virus Disease, United States, February 2022-September 2023.
   Emerg Infect Dis. 2025;31:20-29.
   PubMed         Abstract available
   
   
8. FIORE AE
   Progress Toward Understanding Infection-Associated Chronic Conditions and Illnesses.
   Emerg Infect Dis. 2025;31:1-2.
   PubMed        
   
   
9. GRAY GC, Vlasova AN, Lednicky JA, Nguyen-Tien T, et al
   Emerging Respiratory Virus Threats from Influenza D and Canine Coronavirus HuPn-2018.
   Emerg Infect Dis. 2026;32.
   PubMed         Abstract available
   
   

   
   Int J Infect Dis

10. OSWIN HP, Tellier R, Groth R, Silvonen V, et al
    Quantification of airborne respiratory microflora provides insights into airborne infection risk.
    Int J Infect Dis. 2026 Jan 19:108403. doi: 10.1016/j.ijid.2026.108403.
    PubMed         Abstract available
    
    
11. UEMATSU T, Nojiri S, Nagao M, Ishijima M, et al
    Comprehensive analysis of risk factors for Coronavirus disease 2019 infection and post-infection sequelae based on real-world data from a health insurance database in Japan.
    Int J Infect Dis. 2026 Jan 19:108405. doi: 10.1016/j.ijid.2026.108405.
    PubMed         Abstract available
    
    

    
    J Med Virol

12. MANICA M, Giombini E, Del Manso M, Molina Grane C, et al
    Integrated Genomic and Epidemiological Surveillance to Monitor SARS-CoV-2 Variants in Italy: Insights From the JN.1 Case Study (2023-2024).
    J Med Virol. 2026;98:e70775.
    PubMed         Abstract available
    
    
13. YANG X, Liu Q, Li Y, Lee JZ, et al
    Establishment of a Point-of-Care Testing Method for Rapid Detection of Multiple Respiratory Virus Antigens Based on a Dual-Drive Microfluidic Chip.
    J Med Virol. 2026;98:e70811.
    PubMed         Abstract available
    
    

    
    J Virol

14. TIEN C-F, Lin E-J, Tsai W-H, Tsai W-T, et al
    SARS-CoV-2 spike protein expression drives post-acute coagulopathy.
    J Virol. 2026 Jan 21:e0125525. doi: 10.1128/jvi.01255.
    PubMed         Abstract available
    
    

    
    Lancet

15. PETO J
    The UK COVID-19 Inquiry and the next pandemic.
    Lancet. 2026;407:220-221.
    PubMed        
    
    

    
    Nature

16. 
    AI and nuclear energy feature strongly in agenda-setting technologies for 2026.
    Nature. 2026;649:799.
    PubMed        
    
    

    
    Science

17. KUSCH C, Stegner D, Weiss LJ, Nurden P, et al
    Platelet-derived integrin- and tetraspanin-enriched tethers exacerbate severe inflammation.
    Science. 2026;391:eadu2825.
    PubMed         Abstract available

#Influenza and Other Respiratory Viruses Research #References (by AMEDEO, Jan. 24 '26)

 

Ann Intern Med

1. SACKS HS
   In older adults, RSV prefusion F vaccine reduced hospitalization for RSV-related respiratory tract disease vs. no vaccine.
   Ann Intern Med. 2026 Jan 6. doi: 10.7326/ANNALS-25-05113.
   PubMed         Abstract available
   
   
2. SOUMARE A, Kapfer T, Botrel T, Adda L, et al
   Systemic Corticosteroids, Mortality, and Infections in Pneumonia and Acute Respiratory Distress Syndrome : A Systematic Review and Meta-analysis.
   Ann Intern Med. 2025 Dec 2. doi: 10.7326/ANNALS-25-03055.
   PubMed         Abstract available
   
   

   
   Arch Virol

3. LAI QR, Chen W, Yu GF, Guo YJ, et al
   Molecular epidemiology and clinical characteristics of human adenovirus in children in Hangzhou (2022-2023).
   Arch Virol. 2026;171:60.
   PubMed         Abstract available
   
   

   
   Biochem Biophys Res Commun

4. WU X, Bhatt V, Liu JJ, Hong L, et al
   Single-cell RNA sequencing data analysis reveals differential expressions of ion channels in immunity response to pulmonary COVID-19 infection.
   Biochem Biophys Res Commun. 2026;800:153273.
   PubMed         Abstract available
   
   

   
   BMC Pediatr

5. AYKAC K, Demir OO, Sari MC, Kuruc AI, et al
   Hepatitis is an underestimated complication among children with pneumonia associated with SARS-CoV-2 and influenza: a single center study.
   BMC Pediatr. 2026 Jan 21. doi: 10.1186/s12887-025-06481.
   PubMed        
   
   

   
   BMJ

6. RUSSELL MD, Schaffer A, Bechman K, Gibson M, et al
   Time trends in newly recorded diagnoses of 19 long term conditions before, during, and after the covid-19 pandemic: population based cohort study in England using OpenSAFELY.
   BMJ. 2026;392:e086393.
   PubMed         Abstract available
   
   

   
   Epidemiol Infect

7. WANG B, Zhang T, Yi L, Wu Y, et al
   Incidence of community-acquired pneumonia among adults between 2016 and 2023: an observational cohort study.
   Epidemiol Infect. 2026;154:e15.
   PubMed         Abstract available
   
   
8. DHAWAN S, Pan-Ngum W, MacIntyre CR, Blacksell SD, et al
   Epidemiological indicators of accidental laboratory-origin outbreaks.
   Epidemiol Infect. 2026;154:e16.
   PubMed         Abstract available
   
   

   
   J Infect Dis

9. ZHANG X
   How "Enhanced" Are Enhanced Influenza Vaccines for Neuraminidase? Antigen Content and Baseline Immunity Revisited.
   J Infect Dis. 2026 Jan 23:jiag042. doi: 10.1093.
   PubMed        
   
   
10. ORLINICK B, Mehta S, McAlpine L, Khoshbakht S, et al
    Cerebrospinal Fluid Immune Cell Alterations in Women With Neuropsychiatric Long COVID.
    J Infect Dis. 2026;233:e109-e117.
    PubMed         Abstract available
    
    
11. SONG EM, An HM, Kim SE, Shim KN, et al
    Coronavirus Disease 2019 Risk in Patients With Autoimmune Diseases Using Biologics or Small Molecules: A Population-Based Cohort Study.
    J Infect Dis. 2026;233:137-147.
    PubMed         Abstract available
    
    
12. BIDARI S, Yuan H, Yang W
    Assessing the Transmissibility and Outbreak Risk of Measles in the United States, 2024-2030.
    J Infect Dis. 2026;233:132-136.
    PubMed         Abstract available
    
    

    
    J Virol

13. YANG Q, Xue B, Qiu X, Yang K, et al
    Molecular mechanism of resistance to lonafarnib conferred by mutations in the cysteine-rich region of respiratory syncytial virus fusion glycoprotein and discovery of a lonafarnib-derived antiviral PROTAC.
    J Virol. 2026;100:e0148725.
    PubMed         Abstract available
    
    
14. HAWKINS GM, Qing E, Salgado J, Chan P, et al
    A murine coronavirus infection platform identifies proviral and proinflammatory activities of SARS-CoV-2 accessory protein 7a.
    J Virol. 2025 Dec 16:e0196124. doi: 10.1128/jvi.01961.
    PubMed         Abstract available
    
    
15. FONSECA BF, Robinot R, Michel V, Mendez A, et al
    Stealth replication of SARS-CoV-2 Omicron in the nasal epithelium at physiological temperature.
    J Virol. 2025 Dec 19:e0200825. doi: 10.1128/jvi.02008.
    PubMed         Abstract available
    
    
16. BRIGLEB PH, Sharp B, Lazure L, Livingston B, et al
    Immune history confers antibody- and T cell-dependent cross-protection against highly pathogenic avian influenza H5N1 viruses.
    J Virol. 2026 Jan 22:e0208825. doi: 10.1128/jvi.02088.
    PubMed         Abstract available
    
    

    
    Pediatrics

17. BYINGTON CL, Stellwagen L, Bode L, Hooshmand M, et al
    Milk as a Transmission Vehicle for Highly Pathogenic Avian Influenza A (H5N1).
    Pediatrics. 2026 Jan 22:e2025072525. doi: 10.1542/peds.2025-072525.
    PubMed         Abstract available
    
    

    
    PLoS Comput Biol

18. PELLOW R, Comeron JM
    A wavelet-based approach generates quantitative, scale-free and hierarchical descriptions of 3D genome structures and new biological insights.
    PLoS Comput Biol. 2026;22:e1013887.
    PubMed         Abstract available
    
    
19. ADEGBAJU MS, Owo-Odusi O, Wirtz ET, Morenikeji OB, et al
    Structural analysis of antigenic variation and adaptive evolution of the H5N1 neuraminidase gene.
    PLoS Comput Biol. 2026;22:e1013903.
    PubMed         Abstract available
    
    

    
    PLoS Med

20. TATEMATSU D, Nakamura N, Abe MS, Ishikawa T, et al
    Psychological distress among Japanese high school students during the COVID-19 pandemic: An energy landscape analysis.
    PLoS Med. 2026;23:e1004884.
    PubMed         Abstract available
    
    
21. MONOI A, Endo A, Procter SR, Leuba SI, et al
    The benefits and risks of maternal RSV vaccination on mortality in South Africa: A modeling study.
    PLoS Med. 2026;23:e1004625.
    PubMed         Abstract available
    
    

    
    PLoS One

22. ROHNER S, Schnepper R, Meienberg A, Bopp K, et al
    Protocol of the digital long COVID study: A single-center, registry-based, feasibility and clinical evaluation study to investigate a 12-week digital intervention program for people affected by post-COVID-19 condition.
    PLoS One. 2026;21:e0340385.
    PubMed         Abstract available
    
    
23. PARK J, Koo JH, Kang S
    Urban density and depression during COVID-19 in Seoul: Moderating effects of social participation.
    PLoS One. 2026;21:e0339040.
    PubMed         Abstract available
    
    
24. PATEL N, Sharma R, Lingasamy P, Sundararajan V, et al
    Temporal evolution of digital health communication in Rheumatoid Arthritis: A longitudinal NLP analysis of reddit discussions (2018-2024).
    PLoS One. 2026;21:e0341006.
    PubMed         Abstract available
    
    
25. JOSHI DR, Khanal J, Joshi BM
    Investigating the relationship between teacher efficacy, job satisfaction, and digital resource utilization in assessment practices: Insights from PISA 2018 and 2022.
    PLoS One. 2026;21:e0339475.
    PubMed         Abstract available
    
    
26. ADENIJI OA, Pappas E, Stenner K, Traynor V, et al
    Weathering the storm of COVID-19 pandemic: A cross-sectional survey of reported changes in first contact physiotherapy services in the UK and Australia.
    PLoS One. 2026;21:e0340995.
    PubMed         Abstract available
    
    
27. OKUI T
    Age-specific impact of COVID-19 on birth rates in Japan: An interrupted time-series analysis using national vital statistics.
    PLoS One. 2026;21:e0341340.
    PubMed         Abstract available
    
    
28. LYU Z, Murtaza N
    Impact of crowdfunding, entrepreneurial finance and varieties of entrepreneurial ecosystems after COVID pandemic for rural women.
    PLoS One. 2026;21:e0340966.
    PubMed         Abstract available
    
    
29. MIYAMORI D, Yoshida S, Omori W, Kashima S, et al
    Impact of COVID-19 on new pharmacotherapy for insomnia: A matched cohort study using the national insurance claims database in Japan.
    PLoS One. 2026;21:e0341416.
    PubMed         Abstract available
    
    
30. AGASI-IDENBURG C, de Kruif A, Ronteltap A, van Oers S, et al
    Allied health care in the early stages of the COVID-19 pandemic: A qualitative study on the perceptions of non-hospitalized patients and allied health professionals.
    PLoS One. 2026;21:e0341308.
    PubMed         Abstract available
    
    
31. NOVAK P, Systrom DM, Witte A, Marciano SP, et al
    Shared autonomic phenotype of long COVID and myalgic encephalomyelitis/chronic fatigue syndrome.
    PLoS One. 2026;21:e0341278.
    PubMed         Abstract available
    
    
32. BELALCAZAR AT, Lasso VM, Alvarez Herazo JD, Clarete A, et al
    Rethinking emergency risk assessment: A single-center look at shock index and its variants in COVID-19.
    PLoS One. 2026;21:e0341634.
    PubMed         Abstract available
    
    
33. MACK M, Ye A, Ursu S, Ice R, et al
    HEDGES co-prevents both SARS-CoV-2 and pandemic influenza infection in mice by rapid, durable co-production of twelve different anti-pandemic monoclonal antibodies.
    PLoS One. 2026;21:e0309923.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

34. SRINIVASAN S, King J, Collins JM, Colubri A, et al
    Real-time spatiotemporal tracking of infectious outbreaks in confined environments with a host-pathogen agent-based system.
    Proc Natl Acad Sci U S A. 2026;123:e2422574123.
    PubMed         Abstract available
    
    
35. TE N, Chin AWH, Gu H, Zhirong Jia J, et al
    Broad beta-CoV immunity and transmission blockade by a single-dose live-attenuated vaccine with atypical codon usage.
    Proc Natl Acad Sci U S A. 2026;123:e2518645123.
    PubMed         Abstract available
    
    

    
    Vaccine

36. JEONG O, Choi W, Ahn H, Lee S, et al
    Bromelain-cleaved hemagglutinin production from cell culture-derived influenza viruses enhances vaccine potency quantification by single radial immunodiffusion assay.
    Vaccine. 2026;75:128235.
    PubMed         Abstract available
    
    
37. LISTER H, Farquharson K, Seale H, Smith LE, et al
    Erratum to "A systematic review of the impact of vaccine reactogenicity on willingness to accept influenza vaccination in adults" [Vaccine 74 (2026) 128195].
    Vaccine. 2026;75:128252.
    PubMed        
    
    
38. CONTARINO F, Fiorilla C, Bella F, Orsi A, et al
    Exploring regional variations in the provision of influenza vaccination in Italy.
    Vaccine. 2026;75:128266.
    PubMed         Abstract available
    
    

    
    Virology

39. NGUYEN CT, Nakayama M, Yasui F, Ishigaki H, et al
    Vaccinia virus-based SARS-CoV-2 vaccine prevents lung immunopathology without antibody-dependent enhancement in female rhesus macaques.
    Virology. 2025;616:110778.
    PubMed         Abstract available
    

History of Mass Transportation: The Zentralbahn De 110 005-6 Electric Locomotive in Meiringen BE, Switzerland

 

Par Paebi — Travail personnel, CC BY-SA 3.0, https://commons.wikimedia.org/w/index.php?curid=1054053

Source: 

Link: https://fr.wikipedia.org/wiki/Zentralbahn

____

#Netherlands: #Antibodies to {#H5N1} #birdflu virus found in dairy #cow (Min. Agriculture, Jan. 24 '26)

{Automatic translation from Dutch to English}

Date: January 23, 2026 

Regarding: Dairy cow with antibodies against bird flu 

Dear Chair, Through this letter, I am informing the House, also on behalf of the Minister of Health, Welfare and Sport, about the situation surrounding a dairy cow with antibodies against bird flu (highly pathogenic avian influenza, HPAI). 

No evidence has been found of active virus circulation of bird flu among the dairy cows on this farm in the municipality of Noardeast-Fryslân (province of Friesland). 

There are also no signs of bird flu spreading at other dairy farms. 

I am currently conducting follow-up investigations and have asked all involved parties to be alert to any potential signs. 

Situation: 

The Netherlands Food and Consumer Product Safety Authority (NVWA) received a report on December 24, 2025, about two sick cats. 

One of these cats tested positive for bird flu. 

The cat in question died on December 26, 2025. 

The second cat tested negative and has fully recovered. 

I informed your House of this in my letter of January 13th, including Parliamentary Document 28807, no. 322. 

Following this report, the Netherlands Food and Consumer Product Safety Authority (NVWA) conducted source and contact tracing. 

This revealed a relevant contact with a dairy farm; the cat in question originated from this dairy farm. 

On January 15th, the dairy cattle on this farm were screened. 

Milk samples were taken from several of the cows present, and a sample was also taken from the bulk milk. 

At the time of sampling, no animals showing symptoms of the disease were present on the farm. 

The samples were sent to Wageningen Bioveterinary Research (WBVR) for analysis. 

The results of the PCR tests, which can detect the virus in milk, were negative for both the individual samples and the bulk milk sample. 

This confirmed that no virus was present among the dairy cattle on the farm. 

In addition, the samples were tested for the presence of antibodies. 

On January 20, the WBVR reported that one cow had antibodies to H5N1 avian influenza. 

The presence of antibodies indicates a previous infection with the virus. 

The cow in question had suffered from mastitis and respiratory problems in December. 

These are Symptoms that can be observed in a dairy cow infected with avian influenza. 

At the time of sampling, this cow had recovered. 

Following this positive antibody test, the NVWA (Netherlands Food and Consumer Product Safety Authority) revisited the farm on January 22nd. 

During this visit, blood and milk samples were taken from all cattle present. 

A bulk milk sample was also taken again. 

Today, January 23rd, 2026, the PCR results from these tests were received. 

All but five samples were negative. 

The bulk milk was also PCR negative. 

The five remaining individual milk samples resulted in a test error in the laboratory and will be retested this weekend. 

Based on the PCR results known so far, from last week and today, there is no indication of active circulation of avian influenza virus among the dairy cattle on the farm. 

The five final PCR results will be available this weekend. 

If a positive result is unexpectedly obtained, I will inform Parliament immediately. 

In addition, the results of the antibody testing will follow later next week. 

Antibody testing is important to determine whether more animals have been exposed to the virus, which could indicate past virus circulation. 

Other mammals on the farm (such as dogs, cats, and horses) are currently showing no symptoms. 

Avian influenza in dairy cattle: 

As far as we know, antibodies against avian influenza have not previously been demonstrated in dairy cattle in Europe. 

However, since March 2024, there have been numerous avian influenza outbreaks among dairy cattle in the United States (Parliamentary Document 28807, No. 298). 

The virus causing these outbreaks in dairy cattle in America has not been found in Europe to our knowledge. 

The symptoms exhibited by cows with avian influenza are primarily reduced milk production, fever, loss of appetite, and thick, discolored milk. 

The avian influenza virus is primarily excreted in cows' milk. 

Most dairy cows recover from infection and eventually return to their previous milk production levels. 

It is also possible for a cow infected with avian influenza to show no symptoms; even in that case, the cow often sheds the virus. 

An infected cow sheds infectious virus for about two weeks after infection. 

These symptoms are based on experiences in the US.1 

In response to the large number of avian influenza outbreaks among dairy cows in the US, a policy manual for HPAI in dairy cows2 was developed in early 2025. 

Milk Safety 

Previously, the NVWA's Bureau for Risk Assessment and Research (BuRO) conducted research at the request of the Ministry of Health, Welfare and Sport (VWS) into the management of food and feed safety risks of HPAI virus in milk3. 

In this research It is confirmed that pasteurizing milk completely inactivates the avian influenza virus present. 

The milk is then safe for human consumption and poses no risk to public health or the spread of the virus. 

It is important that raw milk and raw-milk dairy products from cows infected with avian influenza are not consumed. 

Monitoring dairy cattle: 

Individual infection of a dairy cow with the avian influenza virus can occur. 

It is important to know whether this leads to spread within and between farms. 

There are currently no indications that this is the case. 

The basic animal health monitoring program conducts a so-called syndrome surveillance, which involves weekly national and regional monitoring of bulk milk deliveries to determine whether there are any animal health problems in dairy cattle. 

This is a sensitive tool that is particularly valuable when new conditions arise that do not produce specific or noticeable symptoms. 

In addition, the basic monitoring program utilizes pathological examination, and unexplained problems can be reported to the Veekijker (cattle watcher). 

This also makes it possible to identify individual suspected cases of avian influenza infection. 

To date, the basic monitoring has not found any indications that suggest avian influenza infection in dairy cows. 

Naturally, I am closely monitoring the situation and have asked all stakeholders to do so. 

In the short term, I will ask the experts to provide a risk assessment. 

I will also ask experts to analyze possible infection routes and to assess the effectiveness of the monitoring options for HPAI in cattle. 

Furthermore, I have informed stakeholders about this new situation and asked them to report any notable findings. 

Public Health Risk: 

Based on the currently available data, the RIVM (National Institute for Public Health and the Environment) estimates the risk to public health to be very low. 

Because the other cows on the farm also tested negative in the PCR test, it seems unlikely that the virus could have spread from the cow to the other cows. 

Due to the cat that previously tested positive near the farm, individuals working or living on the farm were already known to the Municipal Health Service (GGD). 

These individuals have not shown any symptoms consistent with (avian) influenza since then. 

To be on the safe side, all persons exposed to the cow will still be offered testing for an active or past infection. 

Milk on this farm is used only for pasteurized products, meaning any virus present is inactivated and poses no risk of external contamination. 

Furthermore, the milk from the previously infected cow was not processed for human consumption due to the existing mastitis pattern. 

Therefore, the chance that virus from the infected cow has ended up in the milk for human consumption is very small. 

Given the new situation, the RIVM will soon organize a Zoonosis Response Team (RT-Z) in line with the existing zoonosis structure, in which Experts from human and veterinary health will conduct a risk assessment based on the new situation and share it online. 

Finally, the avian influenza situation in our country remains worrying. 

Unfortunately, outbreaks have occurred in recent weeks on both commercial poultry farms and hobby farms. 

Wild birds are also regularly found with avian influenza. 

The fact that a dairy cow has been infected with the avian influenza virus is therefore consistent with these times of high infection pressure. 

Nevertheless, this is a worrying development. I will therefore continue to closely monitor this situation and will conduct further research. I will inform you, together with the Minister of Health, Welfare and Sport, of relevant developments regarding avian influenza and this case. 

Sincerely, Femke Marije Wiersma, Minister of Agriculture, Fisheries, Food Security and Nature

Source: 

Links: Press Release, https://www.rijksoverheid.nl/onderwerpen/vogelgriep/nieuws/2026/01/23/antistoffen-vogelgriepvirus-gevonden-bij-melkkoe ; Parliamentary Document: https://www.rijksoverheid.nl/onderwerpen/vogelgriep/documenten/kamerstukken/2026/01/23/melkkoe-met-antistoffen-tegen-vogelgriep

____

Intra-patient #neuraminidase #mutations in avian #H5N1 #influenza virus reduce #sialidase activity to complement weaker hemagglutinin binding and facilitate #human infection

 

Abstract

Clade 2.2 H5N1 influenza viruses have caused an unusually high number of human infections, providing a unique opportunity to investigate early molecular steps associated with host adaptation. Although most work has focused on hemagglutinin (HA), the contribution of neuraminidase (NA) to these early adaptive events has remained unclear. By analyzing publicly available sequences from clade 2.2-infected patients, we identified 20 NA mutations and compared their phenotypes to 20 mutations acquired during diversification in primary human airway cells under drug-free conditions. Most patient-derived NA mutations resulted in modest reductions in sialidase activity, keeping activity within a functional range that supported improved replication in α2,6 sialylglycan (α2,6 Sia)-dominant environments, whereas excessive reduction impaired fitness. Notably, the phenotypes of culture-selected and patient-derived mutations were highly concordant, suggesting that these NA changes arose through natural selection rather than antiviral pressure. Re-analysis of patient sequences further revealed that many adaptive NA mutations co-occur with HA mutations that confer only weak, partial α2,6 Sia binding. Using reverse genetics, we found that such naturally occurring HA/NA mutation pairs acted cooperatively in a receptor–context-dependent manner to support α2,6-associated replication relative to HA-only mutants, placing these variants within a constrained “early-adaptation space” characterized by limited α2,6 engagement and moderately reduced NA activity. Together, these findings indicate that early human adaptation of clade 2.2 H5N1 involves not only HA and PB2, but also incremental, cooperative tuning of NA function. Monitoring coordinated HA–NA evolution may therefore improve risk assessment frameworks for zoonotic influenza viruses poised at early stages of human host adaptation.

Source: 

Link: https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1013863

____

#USA, #Wastewater Data for Avian #Influenza #H5 (#CDC, Jan. 23 '26)

 

{Excerpt}

Time Period: January 11, 2026 - January 17, 2026

-- H5 Detection: 6 site(s) (1.1%)

-- No Detection: 519 site(s) (98.9%)

-- No samples in last week: 78 site(s)

(...)

Source: 

Link: https://www.cdc.gov/nwss/rv/wwd-h5.html

____

An #H5N1 clade 2.3.4.4b virus #vaccine that elicits cross-protective #antibodies against conserved domains of H5 and N1 glycoproteins

 

Abstract

The continuous evolution and global spread of highly pathogenic avian influenza (HPAI) H5N1 viruses, particularly clade 2.3.4.4b, pose major challenges for pandemic preparedness. This study evaluates a low-dose inactivated split-virus vaccine derived from H5N1 clade 2.3.4.4b, formulated with an Alum/CpG adjuvant, in a preclinical female mouse model. The vaccine induces strong humoral and cellular immunity, generating high titers of cross-reactive antibodies against diverse H5 hemagglutinin (HA) and across different N1 neuraminidase (NA) glycoproteins. The Alum/CpG adjuvant supports substantial antigen dose sparing and promotes a balanced Th1/Th2 profile. Functional assays show potent virus neutralization, neuraminidase inhibition, and antibody-dependent cellular cytotoxicity, alongside robust antigen-specific CD4+ and CD8+ T cell responses, efficient control of lung viral replication, and reduced lung inflammation. Vaccinated mice are fully protected from lethal challenge with both homologous H5N1 clade 2.3.4.4b and heterologous clade 1 viruses, despite low hemagglutination inhibition (HAI) titers. Electron microscopy polyclonal epitope mapping shows serum antibodies recognizing multiple epitopes on homologous HA and NA, with cross-reactivity to conserved epitopes on heterologous proteins, indicating broad recognition. Together, these findings support this vaccine candidate as a promising strategy to provide broad, multifunctional, and durable immunity against current and emerging H5N1 threats.

Source: 

Link: https://www.nature.com/articles/s41467-026-68457-6

____

#Mpox Multi-country external #situation #report no. 62, published 23 January 2026 (#WHO, summary)

 

Highlights

• All clades of monkeypox virus (MPXV) continue to circulate. 

- Unless mpox outbreaks are rapidly contained and human-to-human transmission is interrupted, there is a risk of sustained community transmission.  

• At the time of reporting, data from the WHO European Region for December 2025 had not yet been submitted; therefore, the information presented below does not include the European Region. 

• In December 2025, 31 countries across five WHO regions (European Region excluded) reported a total of 1040 new confirmed mpox cases, including six deaths (case fatality ratio [CFR] 0.6%). 

- Of these cases, 78% were reported in the African Region. 

- Four regions observed a decline in confirmed cases in December, compared to November 2025, while the Eastern Mediterranean Region reported more cases than the previous month.     

• Fifteen countries in Africa reported active transmission of mpox in the last six weeks (7 December 2025 – 18 January 2026), with 871 confirmed cases, including five deaths (CFR 0.6%). 

- Countries reporting the highest number of cases in this period are the Democratic Republic of the Congo, Guinea, Madagascar, Liberia and Ghana. 

• Four countries, Czechia, Israel, Madagascar and Nepal, and the territory of Mayotte, France, have reported mpox due to clade Ib MPXV for the first time.   

• Outside Africa, community transmission of clade Ib MPXV continues to be reported in France, Italy and Spain. 

- Investigations are ongoing for the case reported in Czechia.  

• Madagascar is reporting an active mpox outbreak, which began in early December 2025 among individuals without recent travel and quickly expanded across the country, which currently is experiencing community transmission of clade Ib MPXV.  

• WHO published ‘Analytical considerations for genomic surveillance of mpox virus’, outlining key considerations for implementing MPXV genomic surveillance, bringing together available evidence and expert input to support the use of pathogen genomics in public health surveillance and response.  

• The report also includes a phylogenetic analysis of MPXV sequences shared on open-source platforms, highlighting the main genetically distinct strains detected in each country since 2022. 

• WHO published the mpox global donor report on 21 January 2026, summarizing donor contributions and funding allocations during the PHEIC period of the mpox response (August 2024– September 2025) across key response priorities 

• On 22 January 2026, the Africa Centres for Disease Control and Prevention lifted the declaration of a Public Health Emergency of Continental Security for mpox.  

Source: 

Link: https://www.who.int/publications/m/item/multi-country-outbreak-of-mpox--external-situation-report--62---23-january-2026

____